{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:25:08Z","timestamp":1759937108223,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"NIH\/NCI Cancer Center Support Grant","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s10549-022-06532-4","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T17:04:11Z","timestamp":1651251851000},"page":"137-148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Synchronous and metachronous bilateral breast cancer among women with a history of lobular carcinoma in situ"],"prefix":"10.1007","volume":"194","author":[{"given":"Melissa Anne","family":"Mallory","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karissa","family":"Whiting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mithat","family":"G\u00f6nen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tari A.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0508-6424","authenticated-orcid":false,"given":"Melissa L.","family":"Pilewskie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"issue":"4","key":"6532_CR1","first-page":"491","volume":"17","author":"FW Foote","year":"1941","unstructured":"Foote FW, Stewart FW (1941) Lobular carcinoma in situ: a rare form of mammary cancer. Am J Pathol 17(4):491\u2013496","journal-title":"Am J Pathol"},{"issue":"12","key":"6532_CR2","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1002\/cncr.20273","volume":"100","author":"ES Hwang","year":"2004","unstructured":"Hwang ES, Nyante SJ, Yi Chen Y, Moore D, DeVries S, Korkola JE, Esserman LJ, Waldman FM (2004) Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. Cancer 100(12):2562\u20132572","journal-title":"Cancer"},{"issue":"1","key":"6532_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.path.2017.09.009","volume":"11","author":"HY Wen","year":"2018","unstructured":"Wen HY, Brogi E (2018) Lobular carcinoma in situ. Surg Pathol Clin 11(1):123\u2013145","journal-title":"Surg Pathol Clin"},{"issue":"4","key":"6532_CR4","doi-asserted-by":"publisher","first-page":"R103","DOI":"10.1186\/bcr3222","volume":"14","author":"VP Andrade","year":"2012","unstructured":"Andrade VP, Ostrovnaya I, Seshan VE, Morrogh M, Giri D, Olvera N, De Brot M, Morrow M, Begg CB, King TA (2012) Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions. Breast Cancer Res 14(4):R103","journal-title":"Breast Cancer Res"},{"issue":"6","key":"6532_CR5","doi-asserted-by":"publisher","first-page":"446","DOI":"10.7326\/0003-4819-143-6-200509200-00009","volume":"143","author":"G Arpino","year":"2005","unstructured":"Arpino G, Laucirica R, Elledge RM (2005) Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med 143(6):446\u2013457","journal-title":"Ann Intern Med"},{"issue":"33","key":"6532_CR6","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1200\/JCO.2015.61.4743","volume":"33","author":"TA King","year":"2015","unstructured":"King TA, Pilewskie M, Muhsen S, Patil S, Mautner SK, Park A, Oskar S, Guerini-Rocco E, Boafo C, Gooch JC, De Brot M, Reis-Filho JS, Morrogh M, Andrade VP, Sakr RA, Morrow M (2015) Lobular carcinoma in situ: a 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk. J Clin Oncol 33(33):3945\u20133952","journal-title":"J Clin Oncol"},{"issue":"12","key":"6532_CR7","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1200\/JCO.2010.32.7395","volume":"29","author":"HB Nichols","year":"2011","unstructured":"Nichols HB, Berrington de Gonzalez A, Lacey JV Jr, Rosenberg PS, Anderson WF (2011) Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol 29(12):1564\u20131569","journal-title":"J Clin Oncol"},{"key":"6532_CR8","first-page":"181","volume":"7","author":"KR Davies","year":"2015","unstructured":"Davies KR, Cantor SB, Brewster AM (2015) Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy. Int J Women\u2019s Health 7:181\u2013187","journal-title":"Int J Women's Health"},{"issue":"8","key":"6532_CR9","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1200\/JCO.1993.11.8.1545","volume":"11","author":"EA Healey","year":"1993","unstructured":"Healey EA, Cook EF, Orav EJ, Schnitt SJ, Connolly JL, Harris JR (1993) Contralateral breast cancer: clinical characteristics and impact on prognosis. J Clin Oncol 11(8):1545\u20131552","journal-title":"J Clin Oncol"},{"issue":"2","key":"6532_CR10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10549-015-3538-5","volume":"153","author":"JJ Jobsen","year":"2015","unstructured":"Jobsen JJ, van der Palen J, Ong F, Riemersma S, Struikmans H (2015) Bilateral breast cancer, synchronous and metachronous; differences and outcome. Breast Cancer Res Treat 153(2):277\u2013283","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"6532_CR11","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1053\/ejso.1999.0711","volume":"25","author":"J Kollias","year":"1999","unstructured":"Kollias J, Ellis IO, Elston CW, Blamey RW (1999) Clinical and histological predictors of contralateral breast cancer. Eur J Surg Oncol 25(6):584\u2013589","journal-title":"Eur J Surg Oncol"},{"key":"6532_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002748.pub3","author":"L Lostumbo","year":"2004","unstructured":"Lostumbo L, Carbine N, Wallace J, Ezzo J (2004) Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD002748.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"23","key":"6532_CR13","doi-asserted-by":"publisher","first-page":"5404","DOI":"10.1002\/cncr.24623","volume":"115","author":"CC McLaughlin","year":"2009","unstructured":"McLaughlin CC, Lillquist PP, Edge SB (2009) Surveillance of prophylactic mastectomy: trends in use from 1995 through 2005. Cancer 115(23):5404\u20135412","journal-title":"Cancer"},{"issue":"10","key":"6532_CR14","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1002\/1097-0142(20010515)91:10<1845::AID-CNCR1205>3.0.CO;2-Z","volume":"91","author":"LA Newman","year":"2001","unstructured":"Newman LA, Sahin AA, Cunningham JE, Bondy ML, Mirza NQ, Vlastos GS, Whitman GJ, Brown H, Buchholz TA, Lee MH, Singletary SE (2001) A case-control study of unilateral and bilateral breast carcinoma patients. Cancer 91(10):1845\u20131853","journal-title":"Cancer"},{"issue":"6","key":"6532_CR15","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1002\/cam4.2198","volume":"8","author":"B Pan","year":"2019","unstructured":"Pan B, Xu Y, Zhou YD, Yao R, Wu HW, Zhu QL, Wang CJ, Mao F, Lin Y, Shen SJ, Sun Q (2019) The prognostic comparison among unilateral, bilateral, synchronous bilateral, and metachronous bilateral breast cancer: a meta-analysis of studies from recent decade (2008\u20132018). Cancer Med 8(6):2908\u20132918","journal-title":"Cancer Med"},{"key":"6532_CR16","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1002\/1097-0142(196412)17:12<1501::AID-CNCR2820171202>3.0.CO;2-P","volume":"17","author":"GF Robbins","year":"1964","unstructured":"Robbins GF, Berg JW (1964) Bilateral primary breast cancer. A prospective clinicopathological study. Cancer 17:1501\u20131527","journal-title":"Cancer"},{"issue":"5","key":"6532_CR17","first-page":"904","volume":"106","author":"PP Rosen","year":"1989","unstructured":"Rosen PP, Groshen S, Kinne DW, Hellman S (1989) Contralateral breast carcinoma: an assessment of risk and prognosis in stage I (T1N0M0) and stage II (T1N1M0) patients with 20-year follow-up. Surgery 106(5):904\u2013910","journal-title":"Surgery"},{"issue":"8","key":"6532_CR18","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1586\/14737140.7.8.1117","volume":"7","author":"T Tuttle","year":"2007","unstructured":"Tuttle T, Habermann E, Abraham A, Emory T, Virnig B (2007) Contralateral prophylactic mastectomy for patients with unilateral breast cancer. Expert Rev Anticancer Ther 7(8):1117\u20131122","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"6532_CR19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10549-007-9709-2","volume":"110","author":"M Schaapveld","year":"2008","unstructured":"Schaapveld M, Visser O, Louwman WJ, Willemse PH, de Vries EG, van der Graaf WT, Otter R, Coebergh JW, van Leeuwen FE (2008) The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat 110(1):189\u2013197","journal-title":"Breast Cancer Res Treat"},{"key":"6532_CR20","first-page":"99","volume":"68","author":"EB Harvey","year":"1985","unstructured":"Harvey EB, Brinton LA (1985) Second cancer following cancer of the breast in Connecticut, 1935\u201382. Natl Cancer Inst Monogr 68:99\u2013112","journal-title":"Natl Cancer Inst Monogr"},{"issue":"4","key":"6532_CR21","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/S0360-3016(03)00203-7","volume":"56","author":"X Gao","year":"2003","unstructured":"Gao X, Fisher SG, Emami B (2003) Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys 56(4):1038\u20131045","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9472","key":"6532_CR22","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (London, England) 365(9472):1687\u20131717","journal-title":"Lancet (London, England)"},{"issue":"23","key":"6532_CR23","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC, Brca, Consortium BC, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402\u20132416","journal-title":"JAMA"},{"issue":"4","key":"6532_CR24","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/JCO.2012.43.2013","volume":"31","author":"AS Reiner","year":"2013","unstructured":"Reiner AS, John EM, Brooks JD, Lynch CF, Bernstein L, Mellemkj\u00e6r L, Malone KE, Knight JA, Capanu M, Teraoka SN, Concannon P, Liang X, Figueiredo JC, Smith SA, Stovall M, Pike MC, Haile RW, Thomas DC, Begg CB, Bernstein JL (2013) Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women\u2019s Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol 31(4):433\u2013439","journal-title":"J Clin Oncol"},{"issue":"1","key":"6532_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13058-017-0874-x","volume":"19","author":"AS Reiner","year":"2017","unstructured":"Reiner AS, Lynch CF, Sisti JS, John EM, Brooks JD, Bernstein L, Knight JA, Hsu L, Concannon P, Mellemkj\u00e6r L, Tischkowitz M, Haile RW, Shen R, Malone KE, Woods M, Liang X, Morrow M, Bernstein JL (2017) Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population. Breast Cancer Res 19(1):83","journal-title":"Breast Cancer Res"},{"issue":"2","key":"6532_CR26","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s10549-013-2725-5","volume":"142","author":"TA King","year":"2013","unstructured":"King TA, Muhsen S, Patil S, Koslow S, Oskar S, Park A, Morrogh M, Sakr RA, Morrow M (2013) Is there a role for routine screening MRI in women with LCIS? Breast Cancer Res Treat 142(2):445\u2013453","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"6532_CR27","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1245\/s10434-017-5867-6","volume":"24","author":"SM Wong","year":"2017","unstructured":"Wong SM, King T, Boileau JF, Barry WT, Golshan M (2017) Population-based analysis of breast cancer incidence and survival outcomes in women diagnosed with lobular carcinoma in situ. Ann Surg Oncol 24(9):2509\u20132517","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"6532_CR28","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1053\/ejso.2002.1266","volume":"28","author":"AR Carmichael","year":"2002","unstructured":"Carmichael AR, Bendall S, Lockerbie L, Prescott R, Bates T (2002) The long-term outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral tumours. Eur J Surg Oncol 28(4):388\u2013391","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"6532_CR29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s12032-010-9785-8","volume":"29","author":"R Diaz","year":"2012","unstructured":"Diaz R, Munarriz B, Santaballa A, Palomar L, Montalar J (2012) Synchronous and metachronous bilateral breast cancer: a long-term single-institution experience. Med Oncol 29(1):16\u201324","journal-title":"Med Oncol"},{"issue":"27","key":"6532_CR30","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2006.10.5056","volume":"25","author":"M Hartman","year":"2007","unstructured":"Hartman M, Czene K, Reilly M, Adolfsson J, Bergh J, Adami HO, Dickman PW, Hall P (2007) Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol 25(27):4210\u20134216","journal-title":"J Clin Oncol"},{"issue":"1","key":"6532_CR31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s10549-010-1057-y","volume":"126","author":"EA Kheirelseid","year":"2011","unstructured":"Kheirelseid EA, Jumustafa H, Miller N, Curran C, Sweeney K, Malone C, McLaughlin R, Newell J, Kerin MJ (2011) Bilateral breast cancer: analysis of incidence, outcome, survival and disease characteristics. Breast Cancer Res Treat 126(1):131\u2013140","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"6532_CR32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13058-021-01400-3","volume":"23","author":"C Ramin","year":"2021","unstructured":"Ramin C, Withrow DR, Davis Lynn BC, Gierach GL, Berrington de Gonz\u00e1lez A (2021) Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992\u20132016. Breast Cancer Res 23(1):24","journal-title":"Breast Cancer Res"},{"issue":"1","key":"6532_CR33","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10549-019-05363-0","volume":"178","author":"T Sakai","year":"2019","unstructured":"Sakai T, Ozkurt E, DeSantis S, Wong SM, Rosenbaum L, Zheng H, Golshan M (2019) National trends of synchronous bilateral breast cancer incidence in the United States. Breast Cancer Res Treat 178(1):161\u2013167","journal-title":"Breast Cancer Res Treat"},{"issue":"36","key":"6532_CR34","doi-asserted-by":"publisher","first-page":"4763","DOI":"10.1200\/JCO.2011.35.0165","volume":"29","author":"AM Nichol","year":"2011","unstructured":"Nichol AM, Yerushalmi R, Tyldesley S, Lesperance M, Bajdik CD, Speers C, Gelmon KA, Olivotto IA (2011) A case-match study comparing unilateral with synchronous bilateral breast cancer outcomes. J Clin Oncol 29(36):4763\u20134768","journal-title":"J Clin Oncol"},{"key":"6532_CR35","volume-title":"The breast: comprehensive management of benign and malignant diseases","author":"A Barrio","year":"2018","unstructured":"Barrio A, Cody HS III (2018) Bilateral breast cancer. In: Bland K, Copeland E, Klimberg VS, Gradishar W (eds) The breast: comprehensive management of benign and malignant diseases, 5th edn. Elsevier, Amsterdam","edition":"5"},{"issue":"7","key":"6532_CR36","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1200\/JCO.1995.13.7.1578","volume":"13","author":"P Bro\u00ebt","year":"1995","unstructured":"Bro\u00ebt P, de la Rochefordi\u00e8re A, Scholl SM, Fourquet A, Mosseri V, Durand JC, Pouillart P, Asselain B (1995) Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol 13(7):1578\u20131583","journal-title":"J Clin Oncol"},{"issue":"4","key":"6532_CR37","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1245\/s10434-011-1907-9","volume":"19","author":"L Fortunato","year":"2012","unstructured":"Fortunato L, Mascaro A, Poccia I, Andrich R, Amini M, Costarelli L, Cortese G, Farina M, Vitelli C (2012) Lobular breast cancer: same survival and local control compared with ductal cancer, but should both be treated the same way? analysis of an institutional database over a 10-year period. Ann Surg Oncol 19(4):1107\u20131114","journal-title":"Ann Surg Oncol"},{"issue":"15","key":"6532_CR38","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1093\/jnci\/djp181","volume":"101","author":"AW Kurian","year":"2009","unstructured":"Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA (2009) Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst 101(15):1058\u20131065","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"6532_CR39","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s10549-012-2183-5","volume":"135","author":"BS Saltzman","year":"2012","unstructured":"Saltzman BS, Malone KE, McDougall JA, Daling JR, Li CI (2012) Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer. Breast Cancer Res Treat 135(3):849\u2013855","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"6532_CR40","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.annepidem.2014.08.003","volume":"24","author":"L Mellemkjaer","year":"2014","unstructured":"Mellemkjaer L, Steding-Jessen M, Frederiksen K, Andersson M, Ejlertsen B, Jensen MB, Olsen JH (2014) Risk of contralateral breast cancer after tamoxifen use among Danish women. Ann Epidemiol 24(11):843\u2013848","journal-title":"Ann Epidemiol"},{"issue":"9132","key":"6532_CR41","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/S0140-6736(98)03301-7","volume":"352","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","year":"1998","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet (London, England) 352(9132):930\u2013942","journal-title":"Lancet (London, England)"},{"issue":"9114","key":"6532_CR42","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","volume":"351","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","year":"1998","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet (London, England) 351(9114):1451\u20131467","journal-title":"Lancet (London, England)"},{"issue":"9922","key":"6532_CR43","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","volume":"383","author":"J Cuzick","year":"2014","unstructured":"Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE, Gv M, Bonanni B, Palva T, Howell A, Investigators I-I (2014) Anastrozole for prevention of breast cancer in high risk post-menopausal women (IBIS-II): an international, double-blind, randomized placebo-controlled trial. Lancet (London, England) 383(9922):1041\u20131048","journal-title":"Lancet (London, England)"},{"issue":"9336","key":"6532_CR44","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","volume":"360","author":"J Cuzick","year":"2002","unstructured":"Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A, Powles T (2002) First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet (London, England) 360(9336):817\u2013824","journal-title":"Lancet (London, England)"},{"issue":"1","key":"6532_CR45","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","volume":"16","author":"J Cuzick","year":"2015","unstructured":"Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF (2015) Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 16(1):67\u201375","journal-title":"Lancet Oncol"},{"issue":"18","key":"6532_CR46","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371\u20131388","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"6532_CR47","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","volume":"295","author":"VG Vogel","year":"2006","unstructured":"Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295(23):2727\u20132741","journal-title":"JAMA"},{"issue":"10218","key":"6532_CR48","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(19)32955-1","volume":"395","author":"J Cuzick","year":"2020","unstructured":"Cuzick J, Sestak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE, Loibl S, Bonanni B, Evans DG, Howell A, Investigators I-I (2020) Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet (London, England) 395(10218):117\u2013122","journal-title":"Lancet (London, England)"},{"issue":"25","key":"6532_CR49","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","volume":"364","author":"PE Goss","year":"2011","unstructured":"Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H, Investigators NCMS (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364(25):2381\u20132391","journal-title":"N Engl J Med"},{"issue":"7","key":"6532_CR50","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1245\/s10434-019-07236-8","volume":"26","author":"MR Flanagan","year":"2019","unstructured":"Flanagan MR, Zabor EC, Stempel M, Mangino DA, Morrow M, Pilewskie ML (2019) Chemoprevention uptake for breast cancer risk reduction varies by risk factor. Ann Surg Oncol 26(7):2127\u20132135","journal-title":"Ann Surg Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06532-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-022-06532-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06532-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T16:19:35Z","timestamp":1654359575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-022-06532-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["6532"],"URL":"https:\/\/doi.org\/10.1007\/s10549-022-06532-4","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2022,4,29]]},"assertion":[{"value":"15 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Tari A. King reports speakers' honoraria from Exact Sciences (formerly Genomic Health), advisory board participation for Exact Sciences, faculty membership with PrecisCa, and Global Advisory Board membership with Besins Healthcare. All other authors have no conflicts of interest or commercial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Institutional Review Board of Memorial Sloan Kettering Cancer Center approved this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}